Synergy CHC Corp. (Uplisting) (SNYR) Competitors $2.50 +0.30 (+13.64%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesOwnershipSEC FilingsTrendsBuy This Stock SNYR vs. MGNX, RENB, ALTS, ANL, VOR, VTGN, IFRX, IGMS, EXOZ, and CLSDShould you be buying Synergy CHC Corp. (Uplisting) stock or one of its competitors? The main competitors of Synergy CHC Corp. (Uplisting) include MacroGenics (MGNX), Renovaro (RENB), Janone (ALTS), Adlai Nortye (ANL), Vor Biopharma (VOR), Vistagen Therapeutics (VTGN), InflaRx (IFRX), IGM Biosciences (IGMS), Exozymes (EXOZ), and Clearside Biomedical (CLSD). These companies are all part of the "pharmaceutical products" industry. Synergy CHC Corp. (Uplisting) vs. MacroGenics Renovaro Janone Adlai Nortye Vor Biopharma Vistagen Therapeutics InflaRx IGM Biosciences Exozymes Clearside Biomedical Synergy CHC Corp. (Uplisting) (NASDAQ:SNYR) and MacroGenics (NASDAQ:MGNX) are both small-cap consumer staples companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, community ranking, dividends, profitability, analyst recommendations, institutional ownership and valuation. Do analysts rate SNYR or MGNX? Synergy CHC Corp. (Uplisting) presently has a consensus price target of $10.00, suggesting a potential upside of 324.63%. MacroGenics has a consensus price target of $7.38, suggesting a potential upside of 527.66%. Given MacroGenics' higher possible upside, analysts clearly believe MacroGenics is more favorable than Synergy CHC Corp. (Uplisting).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synergy CHC Corp. (Uplisting) 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50MacroGenics 0 Sell rating(s) 8 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.36 Do insiders and institutionals hold more shares of SNYR or MGNX? 96.9% of MacroGenics shares are owned by institutional investors. 11.3% of MacroGenics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media prefer SNYR or MGNX? In the previous week, Synergy CHC Corp. (Uplisting) had 4 more articles in the media than MacroGenics. MarketBeat recorded 6 mentions for Synergy CHC Corp. (Uplisting) and 2 mentions for MacroGenics. MacroGenics' average media sentiment score of 1.07 beat Synergy CHC Corp. (Uplisting)'s score of 0.72 indicating that MacroGenics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Synergy CHC Corp. (Uplisting) 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MacroGenics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, SNYR or MGNX? Synergy CHC Corp. (Uplisting) has higher earnings, but lower revenue than MacroGenics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSynergy CHC Corp. (Uplisting)$34.83M0.58N/AN/AN/AMacroGenics$148.34M0.50-$9.06M-$1.08-1.09 Does the MarketBeat Community prefer SNYR or MGNX? MacroGenics received 424 more outperform votes than Synergy CHC Corp. (Uplisting) when rated by MarketBeat users. However, 66.67% of users gave Synergy CHC Corp. (Uplisting) an outperform vote while only 62.10% of users gave MacroGenics an outperform vote. CompanyUnderperformOutperformSynergy CHC Corp. (Uplisting)Outperform Votes266.67% Underperform Votes133.33% MacroGenicsOutperform Votes42662.10% Underperform Votes26037.90% Is SNYR or MGNX more profitable? Synergy CHC Corp. (Uplisting) has a net margin of 0.00% compared to MacroGenics' net margin of -69.07%. Synergy CHC Corp. (Uplisting)'s return on equity of 0.00% beat MacroGenics' return on equity.Company Net Margins Return on Equity Return on Assets Synergy CHC Corp. (Uplisting)N/A N/A N/A MacroGenics -69.07%-89.42%-38.57% SummarySynergy CHC Corp. (Uplisting) and MacroGenics tied by winning 7 of the 14 factors compared between the two stocks. Remove Ads Get Synergy CHC Corp. (Uplisting) News Delivered to You Automatically Sign up to receive the latest news and ratings for SNYR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNYR vs. The Competition Export to ExcelMetricSynergy CHC Corp. (Uplisting)Medicinals & botanicals IndustryStaples SectorNASDAQ ExchangeMarket Cap$20.19M$1.17B$17.03B$7.42BDividend YieldN/AN/A3.02%4.32%P/E RatioN/A9.8615.3317.75Price / Sales0.587.443.6793.57Price / CashN/A10.4016.3934.64Price / BookN/A1.186.263.97Net IncomeN/A-$56.07M$734.35M$247.37M7 Day Performance31.56%4.21%0.58%1.02%1 Month Performance-33.66%-8.90%-1.57%-6.65%1 Year PerformanceN/A-42.70%-1.27%0.06% Synergy CHC Corp. (Uplisting) Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNYRSynergy CHC Corp. (Uplisting)3.127 of 5 stars$2.50+13.6%$10.00+300.0%N/A$21.43M$34.83M0.0040Lockup ExpirationNews CoverageGap UpMGNXMacroGenics3.7135 of 5 stars$1.10+3.8%$7.38+570.5%-92.6%$69.40M$148.34M-0.70430Negative NewsGap DownRENBRenovaro0.5556 of 5 stars$0.43+10.5%N/A-84.8%$68.88MN/A-0.4720Gap DownALTSJanoneN/A$4.26-8.0%N/AN/A$68.50M$12.53M0.00170Short Interest ↑ANLAdlai Nortye1.5453 of 5 stars$1.86-7.7%$9.00+385.2%-81.3%$68.45M$5M0.00127Upcoming EarningsShort Interest ↑Gap DownVORVor Biopharma1.6546 of 5 stars$0.54-4.1%$8.86+1,529.0%-61.1%$67.88MN/A-0.33140Gap DownVTGNVistagen Therapeutics1.9517 of 5 stars$2.17-7.7%N/A-53.3%$67.83M$698,000.00-1.4740IFRXInflaRx2.1505 of 5 stars$1.01flat$9.00+791.1%-20.9%$67.80M$165,789.00-0.9460Short Interest ↑Positive NewsGap DownHigh Trading VolumeIGMSIGM Biosciences4.0546 of 5 stars$1.12-0.9%$5.50+391.1%-86.5%$66.95M$2.68M-0.31190Positive NewsEXOZExozymesN/A$10.65+7.0%N/AN/A$66.58MN/A0.0029CLSDClearside Biomedical2.8745 of 5 stars$0.85-1.8%$5.25+521.1%-36.3%$66.42M$1.66M-1.8830Short Interest ↓ Remove Ads Related Companies and Tools Related Companies MacroGenics Competitors Renovaro Competitors Janone Competitors Adlai Nortye Competitors Vor Biopharma Competitors Vistagen Therapeutics Competitors InflaRx Competitors IGM Biosciences Competitors Exozymes Competitors Clearside Biomedical Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNYR) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredTrump to unlock 15-figure fortune for America (May 3rd) ?Recently, President Trump decided to kill the coin, for good reason. It now costs 4 cents to make a single pen...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synergy CHC Corp. (Uplisting) Please log in to your account or sign up in order to add this asset to your watchlist. Share Synergy CHC Corp. (Uplisting) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
